FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011285271> ?p ?o ?g. }

• W3011285271 endingPage "1125" @default.
• W3011285271 startingPage "1115" @default.
• W3011285271 abstract "Background Many patients with psoriatic arthritis have an inadequate response to tumor necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial. Methods This multicentre, double-blind, randomised, placebo-controlled, phase 3 trial was done at 86 sites in 13 countries across Asia, Australasia, Europe, and North America and enrolled adults with active psoriatic arthritis (at least three swollen and three tender joints; and C-reactive protein ≥0·3 mg/dL) despite standard therapies. Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis. About 30% of study participants could have previously received one or two TNF inhibitors. Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo. The primary endpoint was American College of Rheumatology 20% improvement (ACR20) at week 24 in all patients per assigned treatment group using non-responder imputation. Safety was assessed in all patients per treatment received. This trial is registered at ClinicalTrials.gov, NCT03162796 (active, not recruiting). Findings From Aug 28, 2017, to Aug 17, 2018, we screened 624 patients, of whom 381 were randomly assigned and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126). 362 patients continued study treatment up to week 24. The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50–68]) and every 8 weeks group (66 [52%] of 127 [43–61]) than in the placebo group (28 [22%] of 126 [15–30]), with percentage differences versus placebo of 37% (95% CI 26–48) for the every 4 weeks group and 30% (19–41) for the every 8 weeks group (both p<0·0001). Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo. Up to week 24, one patient in the placebo group died from cardiac failure and two had serious infections; no guselkumab-treated patient died or had serious infections. Interpretation Guselkumab demonstrated a favourable benefit–risk profile and might be an effective treatment option for patients with active psoriatic arthritis. Funding Janssen Research and Development. Many patients with psoriatic arthritis have an inadequate response to tumor necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial. This multicentre, double-blind, randomised, placebo-controlled, phase 3 trial was done at 86 sites in 13 countries across Asia, Australasia, Europe, and North America and enrolled adults with active psoriatic arthritis (at least three swollen and three tender joints; and C-reactive protein ≥0·3 mg/dL) despite standard therapies. Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis. About 30% of study participants could have previously received one or two TNF inhibitors. Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo. The primary endpoint was American College of Rheumatology 20% improvement (ACR20) at week 24 in all patients per assigned treatment group using non-responder imputation. Safety was assessed in all patients per treatment received. This trial is registered at ClinicalTrials.gov, NCT03162796 (active, not recruiting). From Aug 28, 2017, to Aug 17, 2018, we screened 624 patients, of whom 381 were randomly assigned and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126). 362 patients continued study treatment up to week 24. The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50–68]) and every 8 weeks group (66 [52%] of 127 [43–61]) than in the placebo group (28 [22%] of 126 [15–30]), with percentage differences versus placebo of 37% (95% CI 26–48) for the every 4 weeks group and 30% (19–41) for the every 8 weeks group (both p<0·0001). Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo. Up to week 24, one patient in the placebo group died from cardiac failure and two had serious infections; no guselkumab-treated patient died or had serious infections. Guselkumab demonstrated a favourable benefit–risk profile and might be an effective treatment option for patients with active psoriatic arthritis." @default.
• W3011285271 created "2020-03-23" @default.
• W3011285271 creator A5000132079 @default.
• W3011285271 creator A5015084747 @default.
• W3011285271 creator A5016489941 @default.
• W3011285271 creator A5026646005 @default.
• W3011285271 creator A5030325032 @default.
• W3011285271 creator A5031141146 @default.
• W3011285271 creator A5037777681 @default.
• W3011285271 creator A5051239558 @default.
• W3011285271 creator A5055685727 @default.
• W3011285271 creator A5067814311 @default.
• W3011285271 creator A5084697265 @default.
• W3011285271 creator A5090466307 @default.
• W3011285271 date "2020-04-01" @default.
• W3011285271 modified "2023-10-17" @default.
• W3011285271 title "Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial" @default.
• W3011285271 cites W1978022090 @default.
• W3011285271 cites W2004186675 @default.
• W3011285271 cites W2041959340 @default.
• W3011285271 cites W2043900942 @default.
• W3011285271 cites W2101868943 @default.
• W3011285271 cites W2129301243 @default.
• W3011285271 cites W2558568353 @default.
• W3011285271 cites W2570140560 @default.
• W3011285271 cites W2570141807 @default.
• W3011285271 cites W2586118822 @default.
• W3011285271 cites W2616032193 @default.
• W3011285271 cites W2620369605 @default.
• W3011285271 cites W2724955338 @default.
• W3011285271 cites W2730335164 @default.
• W3011285271 cites W2766406067 @default.
• W3011285271 cites W2769254013 @default.
• W3011285271 cites W2805265384 @default.
• W3011285271 cites W2883191655 @default.
• W3011285271 cites W2902697340 @default.
• W3011285271 cites W2911074658 @default.
• W3011285271 cites W2912736897 @default.
• W3011285271 cites W2947452967 @default.
• W3011285271 cites W2989489239 @default.
• W3011285271 cites W3012050575 @default.
• W3011285271 cites W4241915332 @default.
• W3011285271 doi "https://doi.org/10.1016/s0140-6736(20)30265-8" @default.
• W3011285271 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32178765" @default.
• W3011285271 hasPublicationYear "2020" @default.
• W3011285271 type Work @default.
• W3011285271 sameAs 3011285271 @default.
• W3011285271 citedByCount "179" @default.
• W3011285271 countsByYear W30112852712020 @default.
• W3011285271 countsByYear W30112852712021 @default.
• W3011285271 countsByYear W30112852712022 @default.
• W3011285271 countsByYear W30112852712023 @default.
• W3011285271 crossrefType "journal-article" @default.
• W3011285271 hasAuthorship W3011285271A5000132079 @default.
• W3011285271 hasAuthorship W3011285271A5015084747 @default.
• W3011285271 hasAuthorship W3011285271A5016489941 @default.
• W3011285271 hasAuthorship W3011285271A5026646005 @default.
• W3011285271 hasAuthorship W3011285271A5030325032 @default.
• W3011285271 hasAuthorship W3011285271A5031141146 @default.
• W3011285271 hasAuthorship W3011285271A5037777681 @default.
• W3011285271 hasAuthorship W3011285271A5051239558 @default.
• W3011285271 hasAuthorship W3011285271A5055685727 @default.
• W3011285271 hasAuthorship W3011285271A5067814311 @default.
• W3011285271 hasAuthorship W3011285271A5084697265 @default.
• W3011285271 hasAuthorship W3011285271A5090466307 @default.
• W3011285271 hasBestOaLocation W30112852712 @default.
• W3011285271 hasConcept C126322002 @default.
• W3011285271 hasConcept C142724271 @default.
• W3011285271 hasConcept C168563851 @default.
• W3011285271 hasConcept C197934379 @default.
• W3011285271 hasConcept C198451711 @default.
• W3011285271 hasConcept C202061045 @default.
• W3011285271 hasConcept C203092338 @default.
• W3011285271 hasConcept C204787440 @default.
• W3011285271 hasConcept C27081682 @default.
• W3011285271 hasConcept C2776260265 @default.
• W3011285271 hasConcept C2777077863 @default.
• W3011285271 hasConcept C2781427535 @default.
• W3011285271 hasConcept C2991744798 @default.
• W3011285271 hasConcept C71924100 @default.
• W3011285271 hasConceptScore W3011285271C126322002 @default.
• W3011285271 hasConceptScore W3011285271C142724271 @default.
• W3011285271 hasConceptScore W3011285271C168563851 @default.
• W3011285271 hasConceptScore W3011285271C197934379 @default.
• W3011285271 hasConceptScore W3011285271C198451711 @default.
• W3011285271 hasConceptScore W3011285271C202061045 @default.
• W3011285271 hasConceptScore W3011285271C203092338 @default.
• W3011285271 hasConceptScore W3011285271C204787440 @default.
• W3011285271 hasConceptScore W3011285271C27081682 @default.
• W3011285271 hasConceptScore W3011285271C2776260265 @default.
• W3011285271 hasConceptScore W3011285271C2777077863 @default.
• W3011285271 hasConceptScore W3011285271C2781427535 @default.
• W3011285271 hasConceptScore W3011285271C2991744798 @default.
• W3011285271 hasConceptScore W3011285271C71924100 @default.
• W3011285271 hasIssue "10230" @default.
• W3011285271 hasLocation W30112852711 @default.
• W3011285271 hasLocation W30112852712 @default.
• W3011285271 hasLocation W30112852713 @default.

• next